__NUXT_JSONP__("/drugs/Irinotecan_Hydrochloride", (function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p){return {data:[{drug:{slug:f,emaEpar:[],fdaDrugLabel:[{brand:"Irinotecan Hydrochloride 100 mg\u002F5 mL",indication:b,manufacturer:c,splSetId:"2f160344-4ec6-4285-b293-86c0dd40d8b5"},{brand:d,indication:g,manufacturer:h,splSetId:"476fa2a3-8d05-48f6-bc8b-033836828533"},{brand:d,indication:"1 INDICATIONS AND USAGE Irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan hydrochloride injection is a topoisomerase inhibitor indicated for: • First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum, ( 1 ) • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )",manufacturer:"Northstar Rx LLC",splSetId:"4f98e9ed-f7b1-5346-af72-fccb0abf3f4b"},{brand:a,indication:"1 INDICATIONS AND USAGE • Irinotecan Hydrochloride Injection, USP is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan Hydrochloride Injection, USP is a topoisomerase inhibitor indicated for: • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )",manufacturer:"Hospira, Inc.",splSetId:"5c527c2e-9062-4afe-dbbb-f650db3a340f"},{brand:d,indication:g,manufacturer:h,splSetId:"5e1fdcaa-918f-4cd8-9c7a-4c538d866198"},{brand:a,indication:b,manufacturer:c,splSetId:"6a186e60-6ea1-4450-9668-dac7dd7a03e3"},{brand:i,indication:j,manufacturer:"AuroMedics Pharma LLC",splSetId:"7a30d551-9ea7-47ea-9073-f541bff457a3"},{brand:a,indication:"1 INDICATIONS AND USAGE Irinotecan hydrochloride injection, USP is a topoisomerase inhibitor indicated for: First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. ( 1 ) Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 ) • Irinotecan hydrochloride injection, USP is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. • Irinotecan hydrochloride injection, USP is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.",manufacturer:"Areva Pharmaceuticals,Inc.",splSetId:"80f3b79c-a399-45b3-b755-8535457719af"},{brand:"Irinotecan Hydrochloride 40 mg\u002F2 mL",indication:b,manufacturer:c,splSetId:"828932fc-8923-4874-9131-980d5d2a2c86"},{brand:a,indication:"1 INDICATIONS AND USAGE Irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5­-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan hydrochloride injection is a topoisomerase inhibitor indicated for: First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. (1) Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. (1)",manufacturer:"Areva Pharmaceuticals, Inc.",splSetId:"82e95139-6222-f73d-e053-2a91aa0a4810"},{brand:a,indication:k,manufacturer:"Apotex Corp.",splSetId:"85ed6019-f462-4abe-a89e-ad991623c86d"},{brand:a,indication:l,manufacturer:m,splSetId:"9c6aa884-750e-4b11-9955-bc7ab6e9c2ad"},{brand:a,indication:k,manufacturer:"Qilu Pharmaceutical Co., Ltd.",splSetId:"afcdde49-ec0c-4c56-a1af-2917185b1a08"},{brand:e,indication:j,manufacturer:"Xiromed LLC",splSetId:"b26e5d27-dba5-7538-9e7b-48b358998cbb"},{brand:e,indication:n,manufacturer:"BluePoint Laboratories",splSetId:"b66dbd6d-6ccb-ce9d-e053-2995a90a4c3c"},{brand:a,indication:l,manufacturer:m,splSetId:"be716692-6b4f-47b6-83d1-01665861626b"},{brand:"Onivyde",indication:"1 INDICATIONS AND USAGE ONIVYDE ® is indicated, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Limitation of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas [see Clinical Studies (14) ] . ONIVYDE is a topoisomerase inhibitor indicated, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. ( 1 ) Limitation of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas. ( 1 )",manufacturer:"Ipsen Biopharmaceuticals, Inc.",splSetId:"c8b58efa-1820-48a4-b70d-62918fc4abfc"},{brand:a,indication:"1 INDICATIONS AND USAGE Irinotecan Hydrochloride Injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. Irinotecan Hydrochloride Injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan Hydrochloride Injection is a topoisomerase inhibitor indicated for: First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. ( 1 ) Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )",manufacturer:"Sagent Pharmaceuticals",splSetId:"caab50e6-0dad-4ddd-9a6c-96cc2b87aee7"},{brand:a,indication:"1 INDICATIONS AND USAGE Irinotecan hydrochloride injection is a topoisomerase inhibitor indicated for: Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 ) Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.",manufacturer:"Ingenus Pharmaceuticals, LLC",splSetId:"d04f2471-3085-4fc8-a657-bb3918d48e6e"},{brand:e,indication:n,manufacturer:"Gland Pharma Limited",splSetId:"de634e80-328a-4473-b395-0172683a2411"},{brand:o,indication:"1 INDICATIONS AND USAGE CAMPTOSAR is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. CAMPTOSAR is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. CAMPTOSAR is a topoisomerase inhibitor indicated for: First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. ( 1 ) Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )",manufacturer:"Pharmacia and Upjohn Company LLC",splSetId:"e518dfc6-7e93-4fee-a66c-51e1ab71c056"},{brand:a,indication:"1 INDICATIONS AND USAGE Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan hydrochloride injection is a topoisomerase inhibitor indicated for: Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )",manufacturer:"Fresenius Kabi USA, LLC",splSetId:"ee45f127-8450-4455-a945-a1f5707f1d39"}],id:f,nciThesaurus:{casRegistry:"136572-09-3",chebiId:"",chemicalFormula:"C33H38N4O6.HCl.3H2O",definition:"The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.",fdaUniiCode:"042LAQ1IIS",identifier:"C1381",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C2843"],synonyms:["CPT 11","CPT-11","Campto",o,"Camptothecin 11","Camptothecin-11",i,"Irinomedac",a,"Irinotecan Hydrochloride Trihydrate","Irinotecan Monohydrochloride Trihydrate","U-101440E","irinotecan hydrochloride"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FIrinotecan_Hydrochloride",extension:".json",createdAt:p,updatedAt:p}}],fetch:{},mutations:void 0}}("Irinotecan Hydrochloride","1 INDICATIONS AND USAGE Irinotecan hydrochloride injection is a topoisomerase inhibitor indicated for: • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 ) • Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.","Armas Pharmaceuticals Inc.","Irinotecan hydrochloride","Irinotecan hydrochloide","Irinotecan_Hydrochloride","1 INDICATIONS AND USAGE Irinotecan Hydrochloride Injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan Hydrochloride Injection is a topoisomerase inhibitor indicated for: Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )","Actavis Pharma, Inc.","IRINOTECAN HYDROCHLORIDE","1 INDICATIONS AND USAGE Irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan hydrochloride injection is a topoisomerase inhibitor indicated for: First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. ( 1 ) Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )","1 INDICATIONS AND USAGE •Irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. •Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan hydrochloride injection is a topoisomerase inhibitor indicated for: First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. ( 1 ) Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )","1 INDICATIONS AND USAGE Irinotecan Hydrochloride Injection, USP is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan Hydrochloride Injection, USP is a topoisomerase inhibitor indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.","Hikma Pharmaceuticals USA Inc.","1 INDICATIONS AND USAGE Irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan hydrochloride injection is a topoisomerase inhibitor indicated for: • First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. ( 1 ) • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )","Camptosar","2021-10-30T13:32:08.633Z")));